Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
238 results about "Lipid accumulation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lipid accumulation in the brain may be an early sign of Parkinson's disease. FULL STORY. A collaborative team of researchers at McLean Hospital, a Harvard Medical School affiliate, and Oxford University has found that elevated levels of certain types of lipids (fat molecules) in the brain may be an early sign of Parkinson's disease (PD).
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.
Owner:AMICUS THERAPEUTICS INC
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS8399441B2Lower Level RequirementsImprove suppression propertiesOrganic active ingredientsMetabolism disorderLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.
Owner:AMICUS THERAPEUTICS INC
Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
InactiveUS20130273154A1Improve muscle functionImprove coordinationPowder deliveryMicrocapsulesMammalLiver disease
The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.
Owner:SAPIENZA RES LLC +2
Culture method for promoting autotrophy microalgae neutral lipid accumulation
ActiveCN103352006AFacilitate and increase efficiencyFacilitate and enhance accumulationUnicellular algaeMicroorganism based processesBiologyNeutral lipid metabolism
The present invention provides a culture method for promoting autotrophy microalgae neutral lipid accumulation, wherein microalgae having neutral lipid accumulation metabolism capability at a proliferation later stage is subjected to neutral lipid accumulation culture under a 400-550 nm light wave condition. According to the method, under the premise of proliferation culture of the obtained first step cells to achieve the maximum biomass, microalgae neutral lipid metabolism rapidly responses in a short time through temperature reduction on the microalgae liquid and a synergism effect of the illumination condition so as to achieve a purpose of promotion and increase of the neutral lipid accumulation efficiency and the neutral lipid accumulation amount. The blue filter membrane is a plastic film, and can be subjected to large-scale application and modification. The nitrogen limitation stress condition can be achieved through N / P ratio inversion regulation without a microalgae and media separation process. In addition, the process in the large-scale production can be simplified.
Owner:NINGBO UNIV
Methods of treating diabetes and other blood sugar disorders
Evidence is emerging that lipid accumulation in the liver and the muscle contributes to insulin resistance in type II diabetes and the metabolic syndrome (1). This has prompted an investigation of the relationship between lipid accumulation in the liver, serum triglyceride levels, and glucose disposal. These studies demonstrate that liver fat positively correlated to fasting triglyceride levels and negatively correlated to glucose diposal (2). Therefore, strategies to prevent lipid accumulation in liver would have therapeutic value for treatment of type II diabetes, metabolic syndrome and non-alcoholic fatty liver disease. The invention described here relates to continuous administration of GLP-1 or its analogs obtained by either gene or cell therapy that results in reduction serum triglycerides and reduction of lipid accumulation in the liver for treatment of type II diabetes, the metabolic syndrome or non-alcoholic fatty liver disease.
Owner:GENZYME CORP
Method of selecting soybeans with enhanced bioactivity and compositions for reducing cancer cell viability
InactiveUS20110136745A1Lower cholesterol levelsReduce joint painPeptide/protein ingredientsAntipyreticHealth indexCancer cell
The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE2, and expression of iNOS and COX-2; higher antioxidant activity; promotion of growth of bifidobacteria; and inhibiting the growth of pathogenic bacteria; for instance when compared to other seeds tested as hydrolysates. The invention also provides soybean plants for use in producing seeds that have an overall improved bioactivity compared to other seeds as hydrolysates by combining effects on several bioactivity assays in a health index. The invention also provides products derived from, and parts of, these plants and uses thereof. Methods for producing such plants are also provided, as well as methods for standardizing or assuring quality control of soybean products with enhanced bioactivity for humans and animals.
Owner:MONSANTO TECH LLC
Use of leptin for the treatment of fatty liver diseases and conditions
ActiveUS20110212889A1Liver inflammation is reducedDecrease triglyceride accumulationHormone peptidesPeptide/protein ingredientsSteatosisLeptin Deficiency
The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.
Owner:RGT UNIV OF MICHIGAN
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS20100273761A1Improve suppression propertiesDecrease lipid biosynthesisOrganic active ingredientsAntipyreticLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Method for promoting chlorella growth and oil accumulation by carrying out co-culture of alga and bacterium
ActiveCN109609382ANormal growthEfficient oil productionBacteriaUnicellular algaeBacteroidesNormal growth
The invention discloses a method for promoting chlorella growth and oil accumulation by carrying out co-culture of an alga and a bacterium. The method for promoting chlorella growth and oil accumulation by carrying out co-culture of the algae and the bacterium specifically comprise a step of co-culturing chlorella with Mesorhizobium sp. (a nitrogen-fixing bacterium) in certain proportion, so that,oxygen and extracellular metabolites released by the chlorella during growth process can be consumed by the Mesorhizobium sp. while carbon dioxide is metabolized by the Mesorhizobium sp. for photosynthesis of the chlorella cells; moreover, growth stimulators, including vitamins, glycopeptides and the like, are also released so as to promote growth of the chlorella. In addition, nitrogen-fixing capability of the Mesorhizobium sp. is further utilized so as to realize limited nitrogen supply; and thus, normal growth of the chlorella is ensured with efficient oil production of the chlorella cellsrealized.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)
Methods and compositions for induction of ucp1 expression
PendingUS20170173114A1Reduce weightPeptide/protein ingredientsMammal material medical ingredientsAntigenAntigen Binding Fragment
The present invention provides methods and compositions for the induction of expression of UCP1 independent of lipid accumulation. The invention, in particular, features methods for converting FGF receptive cells, e.g., preadipocyte cells, into energy consuming cells through FGF-mediated UCP1 expression. The invention further provides methods and compositions for treating metabolic disorders with an FGF receptor agonist, (e.g., an FGF protein, or fragment thereof, a nucleic acid encoding an FGF protein, an FGF mimetic, an anti-FGF receptor agonist antibody, or antigen binding fragment thereof), or a cell contacted with an FGF receptor agonist, including FGF6.
Owner:JOSLIN D ABETES CENTER INC
Culture method for efficiently inducing lipid accumulation in Botryococcus braunii
InactiveCN101979497APromote divisionPromote accumulationUnicellular algaeMicroorganism based processesNutrient solutionLipid accumulation
The invention discloses a culture method for efficiently inducing lipid accumulation in Botryococcus braunii, which comprises the following steps of: preparing a culture medium and daily added nutrient solution, culturing the Botryococcus braunii for 10 to 18 days of biomass accumulation, introducing CO2 into the Botryococcus braunii culture solution, regulating the concentration of the added nutrient solution, performing ultrasonic treatment on the Botryococcus braunii culture solution for 1 to 3 times by using an ultrasonic instrument at a certain frequency, spacing 10 seconds each time, and treating 5 to 60 seconds each time to inducing the lipid accumulation in the Botryococcus braunii. For the Botryococcus braunii cultured by the method, the biomass is improved by 1 to 1.5 times, thetotal fat content is improved by 30 to 55 percent, and the growth cycle is shortened by 2 to 3 days. A carbon source is supplemented in a mode of introducing CO2; and in the process of producing the lipid accumulation in the Botryococcus braunii on a large scale, a great amount of CO2 waste gas generated in the industrial production process is absorbed, and the method has significance for saving energy, reducing emission and protecting environment.
Owner:北京芳能科技有限公司
Method for promoting accumulation of fucoxanthin and/or lipids in phaeodactylum tricornutum
InactiveCN105132352APromote growthIncreased lipid metabolismUnicellular algaeChemical cell growth stimulationFucoxanthinMicrobiology
The invention discloses a method for promoting accumulation of fucoxanthin and / or lipids in phaeodactylum tricornutum. The method is characterized by including the following steps: inoculating a seawater culture solution with a plurality of phaeodactylum tricornutum in a growing period according to the volume ratio of 10%, adding 2, 4-epibrassinolide into the seawater culture solution to enable the final concentration of the seawater culture solution to be 0.05-0.15mg / L, fully shaking a flask three times a day at the culture temperature of 20 DEG C under the conditions of illumination intensity being 5000lx and photoperiod being 12h / 12h, and culturing 10d of the phaeodactylum tricornutum, wherein the optimal concentration for fucoxanthin accumulation is 0.05mg / L, and the optimal concentration for lipid accumulation is 0.1mg / L. The method has the advantages that through addition of a certain amount of 2, 4-epibrassinolide in a culture medium, the accumulation speed of the fucoxanthin and / or the lipids in the phaeodactylum tricornutum can be increased effectively, and the content of the fucoxanthin and / or the lipids in the phaeodactylum tricornutum can be increased remarkably; the method is simple to operate and low in cost, and production cycle is short.
Owner:NINGBO UNIV
Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals
A method of producing a phytomedicinal therapeutic for the prevention and control of a disease selected from the group consisting of obesity, cardiovascular disease, and diabetes, and conditions related thereto is provided which comprises extracting peanut shells with a solvent, removing a substantial portion of the solvent to produce a concentrated extract. Phytomedicinal compositions are provided that comprise an effective amount of at least one coumarin compound or one coumarin derivative derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL). Phytomedicinal compositions are provided that comprise at least an effective amount of coumarin derivatives (6,7-dihydroxycoumarin-esculetin, and esculetin-like compounds). A method for the prevention and / or treatment of treatment of a condition selected from the group consisting of obesity, cardiovascular disease, and diabetes, is provided which comprises administering a composition comprising an effective amount of at least one coumarin derivative, including 6,7-dihydroxycoumarin (esculetin), derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL).
Owner:RUTGERS THE STATE UNIV
Modulators of lipid metabolism and methods of use
The present invention relates to methods and compositions for modulating lipogenesis, lipid accumulation and lipid metabolism in a cell. These methods and compositions modulate genes which are controlled by LXRα, including the lipogenic transcription factor SREBP-1c.
Owner:CITY OF HOPE
Application of cyclocarya paliurus effective part in preparation of medicine used for treating non-alcoholic fatty liver disease
The invention belongs to the field of pharmaceuticals and relates to application of a cyclocarya paliurus effective part in preparation of health products and medicines which are used for treating a non-alcoholic fatty liver disease. The cyclocarya paliurus effective part mainly contains natural triterpenoid and can be used for effectively reducing rat liver lipid accumulation degree and triglyceride level which are caused by high fat diet, improving the liver histology and liver functions and improving the liver oxidative stress and the organism inflammatory level, so that the cyclocarya paliurus effective part can be used for obviously alleviating non-alcoholic fatty liver disease and preparing health products and medicines which are used for treating the non-alcohol fatty liver disease. The application of the cyclocarya paliurus effective part has the advantage that application range of cyclocarya paliurus preparation in the medical field.
Owner:CHINA PHARM UNIV
New dihydrogen homoisoflavonoid, and preparation method and application thereof
ActiveCN106967031AInhibit lipid accumulationGood lipid-lowering activityOrganic chemistryMetabolism disorderIntracellularTriglyceride
The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.
Owner:HENAN UNIV OF CHINESE MEDICINE
Preparation method of mung bean protein peptide-zinc chelate
ActiveCN109439715APromote absorptionIncrease savingsPeptide preparation methodsFermentationHydrolysateZINC SULFATE HEPTAHYDRATE
The invention relates to a method for making a mung bean protein peptide-zinc chelate. Mung bean protein is used as raw material; the raw material is hydrolyzed by alkaline protease to obtain mung bean polypeptide hydrolysate; and after polypeptide in the mung beanpeptide hydrolysate is freeze-dried, the mung bean polypeptide hydrolysate has a chelation reaction with zinc to obtain the mung bean protein peptide-zinc chelate. The method for making the mung bean protein peptide-zinc chelate, provided by the invention, has the advantages that by chelating the mung bean protein peptide and zinc ions and utilizing a characteristic that the mung bean protein small peptides are easily absorbed by intestinal tracts, the zinc absorption of the intestinal tracts and zinc accumulation in the body canbe promoted, the zinc absorption and utilization rate can be increased, and meanwhile, the zinc ions can be prevented from being lost due to precipitating in alkaline intestinal environment, and thezinc ion dissolving rate and the dialysance of the mung bean protein peptide-zinc chelate after being digested in the stomach and intestine are both higher than those of zinc heptahydrate.
Owner:HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
Bouchardatine, Bouchardatine derivative and preparation methods and applications of Bouchardatine and Bouchardatine derivative
ActiveCN104367575AReduce accumulationReduce formationOrganic active ingredientsOrganic chemistryFatty liverBouchardatine
Disclosed are applications of Bouchardatine and Bouchardatine derivative in preparation of an anti-obesity and fatty liver-relieving drug. The structural fomulas of the Bouchardatine and the Bouchardatine derivative are shown in a pattern (I), to be specific, R is -(CH<2>)<n>R<1>, R<1>is substituted phenyl, heterocyclic radical or substituted amidogen, and n is equal to 0, 1, 2 or 3. By the use of the Bouchardatine and the Bouchardatine derivative, differentiation of pre-adipocyte 3T3-L1 is restrained so as to reduce lipid accumulation in adipocyte 3T3-L1; lipid accumulation, caused by sodium oleate, in hepatoma carcinoma cells is reduced, zooblast triglyceride level is lowered, and anti-obesity and fatty liver-relieving effect is achieved.
Owner:SUN YAT SEN UNIV
Cordyceps militaris sporocarp heteropolysaccharide and application thereof
ActiveCN105585639AReduce savingsAnti-atherosclerotic effectMetabolism disorderCardiovascular disorderArcus aortaeFreeze-drying
The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg / kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.
Owner:TAISHAN MEDICAL UNIV
Reagent or kit for evaluating intestinal lipid accumulation and its intervention, and application and detection method thereof
ActiveCN107632084ADistinguish ability to accurately distinguishStrong resolutionComponent separationGas chromatography–mass spectrometryTest organism
The invention relates to a new application of oleic acid and glycerol 1-monooleate in the preparation of a kit for evaluating the intestinal lipid accumulation in a tested organism and its intervention effect, and a detection method of the oleic acid and the glycerol 1-monooleate. A reagent and the method are used to detect the content of the oleic acid and the glycerol 1-monooleate in the intestinal tissues of the tested organism. The invention further provides the method for detecting the content of the oleic acid and the glycerol 1-monooleate in the intestinal tissues of the tested organismthrough gas chromatography-mass spectrometry. The content can be used for evaluating the intestinal lipid accumulation and its intervention effect. The kit and the detection method have the characteristics of simplicity in operation, good reliability, fastness, high sensitivity, high specificity, and easiness in promotion.
Owner:INST OF URBAN ENVIRONMENT CHINESE ACAD OF SCI
Application of lignan compound
ActiveCN105030802AGood treatment effectLower levelOrganic active ingredientsMetabolism disorderUse medicationTriterpene
The invention belongs to the field of biological medicine, and specifically relates to an application of a lignan compound in the preparation of drugs for reducing blood fat. The disclosed triterpene lignan compound is (-)-syringaresinol-4-O-glucoside, and the structural formula of the lignan compound is represented by the formula (I). The provided compound can prominently inhibit lipid accumulation in-vitro, is capable of obviously reducing the cholesterol and triglyceride in the animal blood of a hyperglycemia model, and has a prominent effect on reducing blood fat. The lignan compound can be used as a novel drug for reducing blood fat, and can be used to treat hyperglycemia, and the drug is user-friendly.
Owner:HAINAN MEDICAL COLLEGE
Application of celastrus orbiculatus alcohol extract in preparing medicine for treating non-alcoholic fatty liver disease (NAFLD)
InactiveCN103142679AHas antioxidant activityReduce sensitivityDigestive systemPlant ingredientsCelastrus orbiculatusPositive control
The invention discloses an application of a celastrus orbiculatus alcohol extract in preparing a medicine for treating non-alcoholic fatty liver disease (NAFLD). By adopting a high-fat diet induced guinea pig NAFLD model and taking simvastatin as a positive control medicine, the celastrus orbiculatus alcohol extract is orally taken for 8 weeks, then influence of the celastrus orbiculatus alcohol extract on NAFLD is observed, and a corresponding mechanism is explored; and the result indicates that the celastrus orbiculatus alcohol extract can be used for obviously improving the high-fat induced pathological alteration of liver tissue, easing the damage of liver cells, reducing the lipid accumulation in liver and suppressing oxidative stress reaction in liver. According to the invention, a new application of the celastrus orbiculatus alcohol extract is developed, and a new means of treating NAFLD is provided.
Owner:TAISHAN MEDICAL UNIV
Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
InactiveUS20170007631A1Small sizeLimitation to intakeOrganic active ingredientsPowder deliveryMammalWeight gain
Owner:APHAIA PHARMA AG
Method and system for producing heterotrophic alga in high density
InactiveCN101899481ALow costBiofuelsMicroorganism based processesLipid formationDocosahexaenoic acid
The invention provides a method and a system for producing heterotrophic alga in high density. In the method, unique biological characteristics of a microbial system are utilized, and the accumulation of lipid is increased by simulating cell division and the uncoupling of cell growth / amount. A process for producing polyunsaturated fatty acid (PUFA) by microalgae fermentation comprises three different stages: (1) a cell proliferation stage for increasing the number of cells; (2) a biomass and lipid accumulation stage for increasing cell biomass, particularly the amount of the lipid; and (3) a lipid concentration increasing stage by refining for producing more PUFA by adjusting the steering of the lipid. Various variables such as the types and concentration of a carbon source and nutritional factors, dissolved oxygen and temperature are changed continuously through a three-stage alga growing process to produce maximum biomass, lipid and docosahexaenoic acid (DHA) by final induction. Therefore, most cell viability leads to the cell division and the rapid formation of a large number of cells, so that the biomass and the lipid yield are integrally enhanced finally.
Owner:WASHINGTON STATE UNIVERSITY +1
Pleurotus eryngii polysaccharide capable of reducing accumulation of foam cell lipid and preparation method thereof
InactiveCN102827305AReduce lipid accumulationHigh yieldAntinoxious agentsFood preparationFood additiveConcentration gradient
The invention discloses a pleurotus eryngii polysaccharide capable of reducing the accumulation of foam cell lipid and a preparation method of the pleurotus eryngii polysaccharide. The pleurotus eryngii polysaccharide is the pleurotus eryngii polysaccharide PEPE-1 of which the average molecular weight is 37.50kDa or the pleurotus eryngii polysaccharide PEPE-2 of which the average molecular weight is 30.00kDa; and the monosaccharide mainly consists of glucose, and a small quantity of mannose and galactose. The preparation method of the pleurotus eryngii polysaccharide comprises the following steps of: digesting and dialyzing pleurotus eryngii sporocarp dry powder by hot water, and further passing through an anion-exchange column DEAE-52 and separating and purifying by the salt concentration gradient elution to obtain PEPE-A; and further separating and purifying the PEPE-A by SephadexG-100, so that the components PEPE-1 and PEPE-2 can be obtained. The PEPE-1 and the PEPE-2 have a single peak, so that the pleurotus eryngii polysaccharide can preferably prevent the foam cell lipid accumulation function and the anti-oxygenation function; and the pleurotus eryngii polysaccharide can be used as a food additive.
Owner:NANJING NORMAL UNIVERSITY
Liver protection effect and application of sulforaphen in non-alcoholic fatty liver
InactiveCN106361740AEffective treatmentReduce accumulationDigestive systemAccessory food factorsGlutamic-Oxaloacetic TransaminaseLiver disease
The invention discloses a liver protection effect and application of sulforaphen in non-alcoholic fatty liver, and belongs to the fields of biomedicine and food. According to the invention, the sulforaphen can be used for effectively treating liver diseases and decelerating lipid accumulation and steatosis of the liver, has the effect of obviously decelerating non-alcoholic fatty liver, and can reduce the glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase levels in blood, thereby opening a new way to treat fatty liver diseases and liver function impairment, having important meanings for development of edible and medicinal dual-purpose resources, realizing high-value transformation of active plant resources and promoting fine and deep processing and utilization of agricultural products. The sulforaphen having a liver protection effect can be widely used in the fields of food, medicine and the like, and has obvious social benefits and economic benefits.
Owner:JIANGNAN UNIV
Functions and use of zinc finger protein A20 in treating fatty liver and type 2 diabetes mellitus
The invention discloses functions and use of zinc finger protein A20 in treating fatty liver and type 2 diabetes mellitus, and belongs to the fields of the functions and the uses of genes. The functions of the A20 are studied by use of high fat diet-induced models; results indicate that the body weight and the fasting blood glucose level of A20 knockout mice in an HFD (High Fat Diet) group both are higher than those of WT mice in a control group; intraperitoneal injection glucose tolerance experiments show that the tolerance ability of the A20 knockout mice to the glucose is obviously weakened; the general liver appearance, the liver weight, the liver / weight ratio, the lipid component pathological staining result and the like of the mice all indicate that the fatty liver lesion of the A20-KO mice in the HFD group is obviously deteriorated and the lipid accumulation is remarkably increased, and the results indicate that the fatty liver and the type 2 diabetes mellitus can be remarkably worsened due to A20 knockout. For the effects of the A20, the A20 can be applied to preparing medicines for preventing, relieving and / or treating the fatty liver and / or the type 2 diabetes mellitus.
Owner:WUHAN UNIV
Application of GGPPS genes in preparation of medicines for treating non-alcoholic fatty liver disease
InactiveCN104415349AReduce lipid accumulationDecelerationGenetic material ingredientsDigestive systemAlanine aminotransferaseAspartate transaminase
The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.
Owner:NANJING UNIV
Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
The present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.
Owner:KOREA INST OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com